
EU Regulation of Genome Editing in Plants – not yet a law
The EU proposal has a clear message: the requirements for simple genome-edited plants shall be significantly relaxed. There will no longer be the...

Mystery solved: Mysthera Theapeutics launches with $3.5m
Mysthera Therapeutics AG was just founded in Basel, Switzerland by Forty51 Ventures with $3.5m seed capital. Pursuing a first-in-class...

Crucible Therapeutics spins out with £5m
Crucible Therapeutics Ltd., the newly launched spinout company from the University of Sheffield, secured the investment of £5m from Northern...

Valneva announces extension of existing loan agreement
An add-on loan provides Valneva SE with immediate access to $50m, with an additional $50m available in Q4/2023. According to the vaccine maker, the...

Novo Nordisk takes over Inversago Pharma Inc.
As competiion for Novo Nordisk A/S’ subcutanously administered blockbuster GLP1-receptor blocker semaglutide is growing, particularly as an obesity...

German company aims for the first EU approval for cell-cultured meat
The Cultivated B (Heidelberg, Germany) is the first company in the world to pre-register a partially cell-based meat product with the European Food...

Bavarian Nordic A/S bags US$120m for smallpox vaccine
Under a deal with the US agency BARDA, Bavarian Nordic A/S (Copenhagen) will cash in US$96m in 2023 ffor the manufacturing of a n new buk product of...